All aspects of application were fine except:

They want the company to distinguish benefit from the device vs physical therapy alone.  This contrasted with previous guidance that the voluminous history of physical therapy alone over the past 50 years and the fact that all patients in the trial had exhausted physical therapy would stand as a control group.  That is why they were granted co primary endpoints of difference between high and low stim groups (just fell short of statistical significance) as well as a change from baseline (highly statistically significant).  The FDA bought off on the trial design and endpoints and even now is acknowledging no safety issues and overall excellent results.  Management will meet with the FDA to arrive at a consensus on how they can do a study to isolate the effect of the device.  One idea is to do a crossover study at the existing sites which continue to enroll patients in a clinical experience program.I’m told that 40 paying patients are being treated in Canada and doing extremely well.

I’ve understandably have received a lot of harsh comments which perhaps I deserve. What you learn when investing in these tiny cap stocks is they can go up 10-100x or they can go to ZERO. I have no idea where this stock goes now. I estimate the company has almost $20,000,000 in the bank and will slash costs. Will the PoNS device end up helping millions of suffering patients from all kinds of neurological diseases? My guess would still be yes.

Back to the point of small cap stocks- 18 months ago when I recommended LFVN at $3.50 a share, I knew it had zero chance of going to zero, and a great chance of going to $10. It went as high as $17. One comment was that I had a winner 10 years ago, but actually I’ve had two winners in the past 3 years. One that went up 400% and LFVN that went up at least 400%. I don’t get paid to give these stock ideas out, these are companies that I know and like. Will HSDT survive this? I am not sure, and with my account at Schwab down $250,000 today, I am still in shock at this news.

I will continue to provide updates to those of you that took my suggestion to buy Helius, a company that is helping people now in Canada, and hopefully one day the rest of the world. If you want to tell me how awful I am, please fire away as I have tough skin.

I hope to get back to writing about golf, and ways to improve your game. I sincerely apologize to those of you that this news and drop in HSDT has hurt. I hope that we all see better days for this company.

Anyone with a GOOD cure for the YIPS, I’d like to hear from you so I can share with the others.

Stay tuned, better days ahead!


I wasn’t sure if I wanted to post this, as many of these exercises are my “secret weapon” in golf. Then I realized I mainly play against the older guys and they are too lazy to try these:)

If you want to improve, stop watching Martin Chuck give you something that doesn’t work, and try these exercises and tell me what helped you most? I give you a money back guarantee that these will. Oh, there is no money required to do these.

Jennifer is the best TPI trainer I’ve ever worked with, and she knows what she’s doing. There is one exercise not on here that I will video that is my #1 exercise (and Jim Furyk’s). So stay tuned for that. But in the meantime try a few of these, the are NOT EASY!!

These specific exercises will significantly improve your range of motion and length of your backswing. And give you a LOT more distance on all your shots.


Let me know how they work for you!!


If you want to keep up with what’s going on in golf, not only the pro game, but with the amateur events then discovered Global Golf Post +

It’s the new subscription service from our favorite golf publication. It delivers original, premium quality content you can’t find anywhere else without any advertising. Of course, you’ll find more of the kind of coverage of the amateur game you have come to expect from GGP. Get a subscription today for just $7/ per month at globalgolfpost.com.

Stay Tuned

Featured Interview: CEO Phillipe Deschamps of Helius Medical Technologies, Inc. (NASDAQ: HSDT)

Ok folks, I PROMISE I will not beat a dead horse here talking about Helius. BUT TAKE 10 Minutes and listen to the interview with the CEO, the link is below!

But after being in the finance field for over 30 years, I have developed a reliable intuitive ability for special situations. This is a special situation where only one company global has a neurological product available that will help millions of people with many different kinds of neurological disorders like MS, Stroke and of course TBI.

The science here is VERY solid, and I’m in this at and average price over $10 a share, and am more bullish than ever. This has upside in the 50-100X range like when I bought ILMN at $3 10 years ago (up 100X+).

So listen to this interview, and remember I told you about this opportunity when the market cap of this company was less than $200M while having a market opportunity in the many billions.

Would love your comments

Interview with Helius Medical CEO


Danielle Suh captures 2019 SF City woman’s title at age 17

In the SF City woman final match 17 year old Danielle Suh defeated Aman Sangha on the 38th hole with two brilliant shots on Hardings tough 2nd hole, leading to a conceded 3 foot putt for birdie and the title.

As history tells us, 17 is no longer considered young in woman golf, as now 13 and 14 year old young ladies are playing world class golf. The men, that’s a different story as a male body will take longer to mature.

I watched this match from the 16th hole thru the 2nd and final hole. Both these young ladies played great golf, and have bright futures in the game.


Here is my interview with Danielle

Randy Haag interview with Women’s SF Champion Danielle Suh


Stay tuned for an interview with the CEO of HSDT you won’t want to miss

103rd San Francisco City Champion Evan Peterson takes down defending Champion Jason Anthony playing great golf

Evan Peterson stands all of 5 foot 9, and barely weighs in at 165 pounds, but can he flat out smack it. This redshirt junior at St Mary’s can easily drive a golf ball 300 yards+ off the tee, check out his powerful swing.

Evan smacking a long drive on the 33rd hole, his final hole of the match

Now take a look at Runner up Jason Anthony’s powerful swing on the final hole.

Jason’s final tee shot on the 33rd hole of the match

What you’ll notice is both players backswings do not reach parallel very similar to John Rahm, but look at the tremendous power they generate with their lags on the downswing. You do NOT need a super long backswing to generate power.

When I started watching this match on the 10th hole of the second 18 holes of the 36 hole final, Jason was 3 down. What I witnesses from then on was some spectacular golf. On the 10th hole both players missed 15 foot birdies tries to hold the match at 3 down. But that’s when the fireworks started on the 11th hole playing 186 yards and  Jason hit a soaring 7 iron to about 12 feet, while Evan hit a poor shot ending up about 80 feet from the pin on the far right fringe of the green while the pin was back left. I gave Evan a 75% chance of 3 putting from that long range distance, and watching his putt race across the green I knew it was going off the green, until it hit the pin dead center and went in for a birdie 2.

Jason then calmly rolled in his 12 foot birdie for a heartbreaking tying 2 on the hole. The 12th hole was again another short game display on Evan’s part by getting a tough bunker shot up and in for a winning birdie while Jason was not able to get his bunker try down in two.

The killer was the 13th hole, just when Jason was going to win the hole 99.95% of the time, as he had an 8 foot birdie attempt, after Evan’s flop to the green raced over the green long leaving him a par chip from 25 feet. As he displayed time and time again Evan calmly chipped it in leaving Jason with a must make putt from 8 feet that didn’t find the bottom, and chance to get the match back to 3 down. 4 down with 5 holes to play is kinda suffocating on the player that is down, while the player enjoying the lead is looking to close things out on the next hole.

The long and tough uphill par 4 14th hole was well played by both players with tying pars to put Jason dormie 4 on the 15th hole. Here again from the left rough Evan hit a spectacular shot to a far left pin from a downhill lie in the rough. Jason last attempt for birdie failed making Evan Peterson the 103rd SF City Champion in grand fashion.

Both players played great golf with Jason hitting 29 out of 33 greens, but it was just Evan’s day. Ironically on day one of match play Evan and Jason exchanged words in the parking lot where Evan mentioned to Jason he felt bad beating his opponent 7&5 while Jason barked back, don’t ever feel bad, just step on em one at a time!! Before the final match Jason reminded Evan that the stepping on em comment was for the others, and not him. Well that didn’t work out so well for our defending champion, but to his credit he won 11 matches in a row, dating back to 2017 as the last time he lost a SF City match, VERY difficult to do, and has not happened many times in the 103 year history of this event.

And yes I do write about my best ball partner with Jason with a lot of love, he is one of the best competitors and most importantly best people I have ever known. I also did enjoyed speaking with the Champion Evan after his wining hole.

Randy Haag interview with 2019 SF CITY Champion Evan Peterson

Ron Kroichick interview with the SF City Champ Evan Peterson

Stay tuned for the Women’s SF  City Championship article that is next




For those of you bold enough to have taken a position in this stock, I congratulate you! My opinion of this opportunity has not wavered at all while the stock went from basically $10 a share down to almost $6.

Last week during high volume trading days the short interest in HSDT went up by about 300,000 share bringing the total short position over 3,000,000 shares. Personally I believe these short positions have a huge problem, why? because their PoNS device works.

We have heard from independent sources from the company that the first 7 patients in Canada have had better than expected results, that could lead to some media coverage next week. The company also has their quarterly earnings call tomorrow.

If you own HSDT consider buying more at these levels, if you don’t own HSDT yet, I’d buy some ASAP. This will end up helping defray the high cost of the game of golf that we love- DISCLOSURE I personally own over 30,000 shares of HSDT, I am not retained or paid by the company, or anyone to tell you about this opportunity. I believe their PoNS device will help millions of people globally.

HSDT to Release Fourth Quarter and Fiscal Year 2018 Financial Results On March 14, 2019 – Market News Publishing

07-Feb-2019 05:35:42 AM


HELIUS MEDICAL TECHNOLOGIES INC (“HSM-T;HSDT-Q”) – To Release Fourth Quarter and Fiscal Year 2018 Financial Results – On March 14, 2019

Helius Medical Technologies, Inc. (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that fourth quarter and fiscal year 2018 financial results will be released after the market closes on Thursday, March 14.

Management will host a conference call at 4:30 p.m. Eastern Time on March 14 to discuss the results of the quarter and the year. Those who would like to participate may dial 866-393-4306 (734-385-2616 for international callers) and provide access code 8929969. A live webcast of the call will also be provided on the Events section of the Company’s investor relations website at  -events.

For those unable to participate, a replay of the call will be available for two weeks at 855-859-2056 (404-537-3406 for international callers); access code 8929969. The webcast will be archived on the Events section of the Company’s investor relations website.

About Helius Medical Technologies, Inc.

Helius Medical Technologies is a neurotech company focused on neurological wellness. The Company’s purpose is to develop, license and acquire unique and non-invasive platform technologies that amplify the brain’s ability to heal itself. The Company’s first product in development is the Portable Neuromodulation Stimulator (PoNS). For more information, visit www.heliusmedical.com.

About the PoNS Device and PoNS Treatment

The Portable Neuromodulation Stimulator (PoNS) is an investigational, non-invasive, medical device in the United States, for which Helius has requested De Novo classification and 510(k) clearance from the Food and Drug Administration for the treatment of chronic balance deficit due to mild-to-moderate traumatic brain injury when combined with targeted physical therapy. PoNS is a licensed class II medical device in Canada. PoNS is currently not commercially available in the United States or the European Union. Investor Relations Contact: Westwicke Partners on behalf of Helius Medical Technologies, Inc. Mike Piccinino, CFA 443-213-0500 investorrelations@heliusmedical.com